Literature DB >> 15844317

Application of lornoxicam to patient-controlled analgesia in patients undergoing abdominal surgeries.

Hong Zhao1, Tie-hu Ye, Zhi-yi Gong, Yang Xue, Zhang-gang Xue, Wen-qi Huang.   

Abstract

OBJECTIVE: To assess the efficacy and safety of lornoxicam, one non-steroidal anti-inflammatory drug (NSAID) in patient-controlled analgesia (PCA) in patients undergoing abdominal surgeries.
METHODS: Thirty-nine patients scheduled for abdominal surgeries were randomly assigned to different PCA treatment groups using either lornoxicam or fentanyl postoperatively. Pain intensity difference (PID) and sum of pain intensity difference (SPID) were used to assess the analgesic efficacy of both drugs during a 24-hour period.
RESULTS: The analgesic efficacy of lornoxicam is 1/66 of fentanyl, which was shown by SPID value of 3.250 and 3.058, respectively (P > 0.05). Lornoxicam caused fewer adverse events than fentanyl (33% vs. 68%, P < 0.05).
CONCLUSION: In clinic, we can use lornoxicam to treat postoperative pain effectively and with less adverse reactions compared with fentanyl.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15844317

Source DB:  PubMed          Journal:  Chin Med Sci J        ISSN: 1001-9294


  3 in total

1.  Effects of lornoxicam on the hemodynamic and catecholamine response to laryngoscopy and tracheal intubation.

Authors:  Mohamed Daabiss; Mohamed Hashish
Journal:  Eur J Clin Pharmacol       Date:  2011-03-03       Impact factor: 2.953

2.  Comparison between lornoxicam quick-release and parecoxib for post-operative analgesia after laparoscopic cholecystectomy: A prospective randomized, placebo-controlled trial.

Authors:  Irene Kouroukli; Vasilios Zompolas; Vasiliki Tsekoura; Ioannis Papazoglou; Antonis Louizos; Venetiana Panaretou
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2013-10

3.  Incompatibilities of lornoxicam with 4 antiemetic medications in polyolefin bags during simulated intravenous administration.

Authors:  Bao-Xia Fang; Peng Li; Xiao-Ya Shi; Fu-Chao Chen; Lin-Hai Wang
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.